Cell based approaches for evaluation of drug-induced liver injury.
about
Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver InjuryKey Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansTransgenic mice and metabolomics for study of hepatic xenobiotic metabolism and toxicityHigh-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.Bioreactor technologies to support liver function in vitro.Differential effect of troglitazone on the human bile acid transporters, MRP2 and BSEP, in the PXB hepatic chimeric mouse.Evaluation of an in vitro toxicogenetic mouse model for hepatotoxicityCharacterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins.WITHDRAWN--a resource for withdrawn and discontinued drugsBiosynthesis and trafficking of the bile salt export pump, BSEP: therapeutic implications of BSEP mutations.Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues.Primary hepatocyte cultures as prominent in vitro tools to study hepatic drug transporters.Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury.Hepatobiliary transporters in drug-induced cholestasis: a perspective on the current identifying tools.Competency of different cell models to predict human hepatotoxic drugs.Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.Liver Cell Culture Devices.A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells.A simple and economical route to generate functional hepatocyte-like cells from hESCs and their application in evaluating alcohol induced liver damage.Predicting in vivo safety characteristics using physiochemical properties and in vitro assays.A metabolomics cell-based approach for anticipating and investigating drug-induced liver injury.Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.Sertraline, an antidepressant, induces apoptosis in hepatic cells through the mitogen-activated protein kinase pathway.Mixed learning algorithms and features ensemble in hepatotoxicity prediction.Quantitative analysis of cytochrome P450 isoforms in human liver microsomes by the combination of proteomics and chemical probe-based assay.The in silico identification of human bile salt export pump (ABCB11) inhibitors associated with cholestatic drug-induced liver injury.Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.LC-MS untargeted metabolomic analysis of drug-induced hepatotoxicity in HepG2 cells.Identification of Epoxide-Derived Metabolite(s) of Benzbromarone.Mechanisms of tolvaptan-induced toxicity in HepG2 cells.
P2860
Q26781923-6496C0CB-0DDB-4FA8-857F-3D22B5D5B19CQ28075991-03BD6C1D-A52E-44F3-B808-D5F1C15AF72AQ28087473-6E8F10A3-2172-47D1-A940-7F4C78EA0558Q34044936-B245F8EE-FE0A-465C-A56B-6BEFC33CCFABQ34087508-044CE96A-ED07-4378-BAE2-00F0D90AF446Q34294773-9FE33107-53D0-4C92-A3F4-784C15490327Q34306388-11713B8D-A75B-437E-B041-E26F52D9FE1DQ35828228-634FBCE1-D376-42AF-9D2D-AF51292E8325Q36434790-51459E41-DE5C-42B5-90D6-BF3CCA5C8D4BQ37200971-3C53D51A-5351-4D78-AA64-3FD1206ED490Q37665888-CE04679A-876E-4DD1-BE25-A8EF8DAA79F8Q38077993-5CA1D4DB-DF88-4D2A-8710-9714378A6FC7Q38161471-71434C74-FF39-4399-AFFB-9E76EBB1D34CQ38192698-C3D6F733-A871-4632-B216-3739E35B4C1AQ38258251-73C0ABAA-C619-4CB3-AC59-D5B463024DCCQ38675826-82C097CD-AA4E-4B11-9BED-486E7BB18EABQ38960582-750A63BD-9166-49A4-B814-C443B1E14723Q39089080-16102617-B034-40B3-8796-4BB12A6EA670Q39146738-6F1E91DE-A710-494B-9E90-192319815FF0Q39466419-AF3ACA6B-70CC-4340-81CC-2317BB07D4E1Q39481089-147B873E-BB2C-408D-8AE2-ECDEC668C121Q39707536-8F2CF927-237D-4297-BF12-C7E16C5B0E42Q40684311-854C4E84-5DDE-44E4-9DD9-9ABBA62E3311Q42708571-A3150FD0-6E31-486A-A299-0E56F978DF78Q45372748-D49DDF4A-826B-42DE-9D6E-B9E44752A1B0Q46709200-9190960C-ED27-46FF-8A6D-73FC1AB326CCQ48349259-242FBCB5-1E41-4AF1-B4E9-CFA0EB2F4BE6Q49219661-1F2274CD-71E8-401B-9A7F-4F21CE37EC71Q50443932-0BCA5D43-6605-4498-B105-9520E54D0491Q50539283-E619CACE-3515-406A-B0E6-1845446994E9Q55061705-AF4B5B86-1A60-4D24-AB97-F4B79AA32F0C
P2860
Cell based approaches for evaluation of drug-induced liver injury.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cell based approaches for evaluation of drug-induced liver injury.
@en
Cell based approaches for evaluation of drug-induced liver injury.
@nl
type
label
Cell based approaches for evaluation of drug-induced liver injury.
@en
Cell based approaches for evaluation of drug-induced liver injury.
@nl
prefLabel
Cell based approaches for evaluation of drug-induced liver injury.
@en
Cell based approaches for evaluation of drug-induced liver injury.
@nl
P2093
P1433
P1476
Cell based approaches for evaluation of drug-induced liver injury
@en
P2093
Jane Barber
Julie Eakins
Mhairi L Greer
P304
P356
10.1016/J.TOX.2009.08.007
P407
P577
2009-08-13T00:00:00Z